Dynavision earns the majority of its income from leasing a large commercial property to Apollo Hospitals and has recently expanded into providing engineering and construction services for solar power projects.
While the company shows exceptionally high margins and returns, these are artifacts of a legacy real estate asset being fully depreciated rather than a competitive advantage. The new solar EPC business is a commodity service with no evidence of brand power or cost advantages that would protect long-term profitability.
Management is pivoting from a stable, cash-generating rental model into capital-intensive solar projects and healthcare manufacturing research. They have used internal cash to fund a subsidiary's solar expansion and are currently prioritizing resource conservation over dividends.
The illusion of high-quality earnings evaporated as the legacy real estate assets fully depreciated, revealing a core business that had pivoted into a low-margin, commodity solar EPC trap. Management's decision to abandon a stable rental model for capital-intensive ventures in healthcare and solar led to significant cash burn and poor capital allocation. By year five, the heavy concentration in related-party contracts with Apollo-affiliated entities proved fatal when those terms were renegotiated or discontinued, leaving the company with stagnant revenue and no competitive leverage in a crowded marketplace.
RichFakir rates Dynavision Ltd's business quality as decent — 70/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Dynavision Ltd is trading about 36% below our estimate of fair value; we rate its price cheap. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Dynavision Ltd is: Buy candidate. A decent business trading below what we think it is worth — so it makes our buy list.
RichFakir's educational estimate of Dynavision Ltd's fair value is about ₹355 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →